Ponesimod Shown Promising for MRI Outcomes in Relapsing MS
Compared to teriflunomide, ponesimod showed benefit for magnetic resonance imaging (MRI) outcomes in relapsing multiple sclerosis.
Compared to teriflunomide, ponesimod showed benefit for magnetic resonance imaging (MRI) outcomes in relapsing multiple sclerosis.
ADS-5102, the extended release capsule form of amantadine, may clinically benefit walking speed in patients with multiple sclerosis.
In secondary progressive multiple sclerosis, amiloride, fluoxetine, and rizuole treatments do not translate into long-term reduction in atrophy rates.
Baseline levels of ubiquitin C-terminal hydrolase L1 in cerebral spinal fluid may be predictive of long term multiple sclerosis progression.
The terminal complement inhibitor eculizumab reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
Ozanimod may be a safe and well-tolerated treatment for relapsing forms of multiple sclerosis.
Individuals with relapsing-remitting MS who respond suboptimally to DMT may experience improvement with the addition of an SSRI.
Researchers analyzed whether hypertension onset occurs at an earlier age in individuals with multiple sclerosis who were born post-1965.
The Wahls elimination diet had more significant effects on quality of life for individuals with relapsing-remitting multiple sclerosis as compared to the Swank diet.
Effectiveness of disease modifying therapies for multiple sclerosis was shown to be associated with shorter disease duration and lower relapse rate.